Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?

17.04.25 18:10 Uhr

Werte in diesem Artikel
Aktien

249,50 EUR 4,60 EUR 1,88%

Indizes

5.282,7 PKT 7,0 PKT 0,13%

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Cencora (COR), which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This prescription drug distributor has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 5.31%.For the last reported quarter, Cencora came out with earnings of $3.73 per share versus the Zacks Consensus Estimate of $3.50 per share, representing a surprise of 6.57%. For the previous quarter, the company was expected to post earnings of $3.21 per share and it actually produced earnings of $3.34 per share, delivering a surprise of 4.05%.Price and EPS SurpriseWith this earnings history in mind, recent estimates have been moving higher for Cencora. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Cencora has an Earnings ESP of +0.91% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on May 7, 2025.With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Cencora und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Cencora

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Cencora

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Cencora

Wer­bung

Analysen zu Cencora

DatumRatingAnalyst
20.07.2018AmerisourceBergen NeutralRobert W. Baird & Co. Incorporated
08.03.2018AmerisourceBergen Equal WeightBarclays Capital
08.02.2018AmerisourceBergen BuyNeedham & Company, LLC
30.01.2018AmerisourceBergen BuyNeedham & Company, LLC
23.01.2018AmerisourceBergen BuyNeedham & Company, LLC
DatumRatingAnalyst
08.02.2018AmerisourceBergen BuyNeedham & Company, LLC
30.01.2018AmerisourceBergen BuyNeedham & Company, LLC
23.01.2018AmerisourceBergen BuyNeedham & Company, LLC
04.12.2017AmerisourceBergen BuyDeutsche Bank AG
22.11.2017AmerisourceBergen BuyNeedham & Company, LLC
DatumRatingAnalyst
20.07.2018AmerisourceBergen NeutralRobert W. Baird & Co. Incorporated
08.03.2018AmerisourceBergen Equal WeightBarclays Capital
19.09.2017AmerisourceBergen Sector PerformRBC Capital Markets
04.08.2017AmerisourceBergen NeutralUBS AG
30.05.2017AmerisourceBergen NeutralMizuho
DatumRatingAnalyst
14.05.2007AmerisourceBergen reduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Cencora nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen